CA2969940A1 - Anticorps anti-trka a proprietes inhibitrices ameliorees et derives desdits anticorps destines a etre utilises pour traiter les douleurs osseuses - Google Patents
Anticorps anti-trka a proprietes inhibitrices ameliorees et derives desdits anticorps destines a etre utilises pour traiter les douleurs osseuses Download PDFInfo
- Publication number
- CA2969940A1 CA2969940A1 CA2969940A CA2969940A CA2969940A1 CA 2969940 A1 CA2969940 A1 CA 2969940A1 CA 2969940 A CA2969940 A CA 2969940A CA 2969940 A CA2969940 A CA 2969940A CA 2969940 A1 CA2969940 A1 CA 2969940A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- trka
- antibodies
- pain
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
La présente invention concerne des anticorps dirigés contre le récepteur TrkA et leurs utilisations, y compris des anticorps anti-TrkA humanisés, et des méthodes de traitement avec des anticorps anti-TrkA.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/562,297 US20150183885A1 (en) | 2012-06-08 | 2014-12-05 | Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof |
US14/562,297 | 2014-12-05 | ||
EP15165107.2 | 2015-04-24 | ||
EP15165107 | 2015-04-24 | ||
PCT/EP2015/078875 WO2016087677A1 (fr) | 2014-12-05 | 2015-12-07 | Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2969940A1 true CA2969940A1 (fr) | 2016-06-09 |
Family
ID=54838344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2969940A Abandoned CA2969940A1 (fr) | 2014-12-05 | 2015-12-07 | Anticorps anti-trka a proprietes inhibitrices ameliorees et derives desdits anticorps destines a etre utilises pour traiter les douleurs osseuses |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP3227334A1 (fr) |
JP (1) | JP2018505853A (fr) |
CN (1) | CN107207599A (fr) |
CA (1) | CA2969940A1 (fr) |
HK (1) | HK1244012A1 (fr) |
MA (1) | MA41097A (fr) |
WO (1) | WO2016087677A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116327963A (zh) | 2016-11-21 | 2023-06-27 | 济世-伊沃泰克生物制品有限公司 | 一种眼科制剂及其用途 |
JP7183268B2 (ja) * | 2017-11-20 | 2022-12-05 | ジャスト-エヴォテック バイオロジックス、インコーポレイテッド | 等張化剤としてリジン塩を含有するアフリベルセプト製剤及びその使用 |
AR114110A1 (es) * | 2018-02-28 | 2020-07-22 | Lilly Co Eli | Anticuerpo anti-trka |
EP3976657A4 (fr) * | 2019-05-30 | 2023-07-05 | Sunshine Lake Pharma Co., Ltd. | Anticorps anti-trka et leurs utilisations |
TW202210467A (zh) | 2020-05-28 | 2022-03-16 | 美商美國禮來大藥廠 | TrkA抑制劑 |
WO2023125477A1 (fr) * | 2021-12-28 | 2023-07-06 | 4B Technologies (Beijing) Co., Limited | Anticorps trka et son application |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1306704B1 (it) * | 1999-05-26 | 2001-10-02 | Sirs Societa Italiana Per La R | Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf. |
US7569364B2 (en) * | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
ITRM20030601A1 (it) * | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
RU2433139C2 (ru) * | 2005-05-20 | 2011-11-10 | Аблинкс Н.В. | Nanobodies tm для лечения заболеваний, опосредованных агрегацией |
ITRM20050290A1 (it) * | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
ITRM20050332A1 (it) * | 2005-06-24 | 2006-12-25 | Lay Line Genomics Spa | Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore. |
AU2009211340B2 (en) * | 2008-02-04 | 2013-09-12 | Lay Line Genomics S.P.A. | Anti-TrkA antibodies and derivatives thereof |
WO2012075340A2 (fr) * | 2010-12-01 | 2012-06-07 | Alderbio Holdings Llc | Compositions anti-ngf et leur utilisation |
ES2666126T3 (es) * | 2012-06-08 | 2018-05-03 | Glenmark Pharmaceuticals S.A. | Anticuerpos anti-TrkA humanizados con sustituciones de aminoácidos |
-
2015
- 2015-12-06 MA MA041097A patent/MA41097A/fr unknown
- 2015-12-07 CA CA2969940A patent/CA2969940A1/fr not_active Abandoned
- 2015-12-07 JP JP2017529765A patent/JP2018505853A/ja active Pending
- 2015-12-07 EP EP15807645.5A patent/EP3227334A1/fr not_active Withdrawn
- 2015-12-07 WO PCT/EP2015/078875 patent/WO2016087677A1/fr active Application Filing
- 2015-12-07 CN CN201580075478.3A patent/CN107207599A/zh not_active Withdrawn
-
2018
- 2018-03-12 HK HK18103438.4A patent/HK1244012A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP3227334A1 (fr) | 2017-10-11 |
CN107207599A (zh) | 2017-09-26 |
HK1244012A1 (zh) | 2018-07-27 |
JP2018505853A (ja) | 2018-03-01 |
MA41097A (fr) | 2017-10-10 |
WO2016087677A1 (fr) | 2016-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2859019B1 (fr) | Anticorps humanisés anti-trka avec substitutions d'acides aminés | |
US11407839B2 (en) | Antibodies that bind to OX40 and their uses | |
US20200079863A1 (en) | Antibodies that bind to tl1a and their uses | |
RU2473564C2 (ru) | Антитела человека с высокой аффинностью к фактору роста нервов человека | |
CA2969940A1 (fr) | Anticorps anti-trka a proprietes inhibitrices ameliorees et derives desdits anticorps destines a etre utilises pour traiter les douleurs osseuses | |
KR20210131336A (ko) | Il-7r 알파 서브유닛에 대한 항체 및 이의 용도 | |
CA2938066A1 (fr) | Proteine chimerique composee d'un domaine antagoniste de ngf et d'un domaine antagoniste de tnfa | |
US20160319027A1 (en) | Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof | |
US20170362327A1 (en) | Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof for use in treating bone associated pain | |
WO2023125490A1 (fr) | Anticorps anti-trka et application de celui-ci | |
OA17182A (en) | Humanized anti-TrkA antibodies with amino acid substitutions. | |
WO2023250415A2 (fr) | Anticorps ciblant l'intégrine alpha 11 bêta 1 et leurs utilisations | |
NZ619849B2 (en) | Antibodies that bind to ox40 and their uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |
Effective date: 20220301 |